# US FDA issues warning letter to Aurobindo Pharma unit 2026-08-14T11:04:21+00:00 | Business & Economy | Indian Opinion Desk Corroboration: 1 independent outlet The US Food and Drug Administration has issued a warning letter to Unit I of Eugia Pharma Specialities, a subsidiary of Aurobindo Pharma near Hyderabad. The action follows four observations from an inspection in February and an Official Action Indicated (OAI) status in May. Aurobindo Pharma said on Friday (August 14) the letter does not affect existing US supplies. The unit contributes about 2% of group revenue. Shares fell 1.25% to Rs 1,636.20 on BSE, recovering from early losses. ## Coverage - thehindu.com Tags: Aurobindo Pharma, Eugia Pharma, Hyderabad, Pharmaceutical Compliance, US FDA, Warning Letter Canonical: https://indianopinion.org/us-fda-issues-warning-letter-to-aurobindo-pharma-unit/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/us-fda-issues-warning-letter-to-aurobindo-pharma-unit/#story-in-brief Review state: restored archive article, accurate at time of publication, not offered to search indexes.